PubMed Health⌕ Search

PubMed · 9288026

What does cell death have to do with aging?

Abstract

When Lockshin and Zakeri discussed the relevance of apoptosis to aging 7 years ago, the common view was that apoptosis would have primarily a negative impact on aging by destroying essential and often irreplaceable cells. That view has now changed to one that acknowledges that there are two general ways in which apoptosis can play a role in aging: (1) elimination of damaged and presumably dysfunctional cells (e.g., fibroblasts, hepatocytes), which can then be replaced by cell proliferation, thereby maintaining homeostasis, and (2) elimination of essential post-mitotic cells (e.g., neurons, cardiac myocytes), which cannot be replaced, thereby leading to pathology. Evidence exists in two systems (fibroblasts and thymocytes/lymphocytes) that there are age-related decreases in the potential for apoptosis, although the molecular bases for the decreases in these two systems appear to differ. Upon becoming senescent, fibroblasts lose the ability to down-regulate expression of the bcl-2 gene in response to an apoptotic signal; thus, apoptosis is blocked even though an initiating signal has been received. In contrast, thymocytes/lymphocytes lack the ability to initiate the signal because of down-regulation of the cell surface receptor Fas. There is limited information available for other tissue types, and nothing is known about why and how age-related changes occur. An interesting observation is that the frequency of up-regulation of the bcl-2 gene as a result of chromosome translocation in otherwise normal B cells increases with age; the functional consequences of this phenomenon during aging are not known. The role of apoptosis in regulating cell number is also a promising area of research. The studies on liver damage and neoplastic lesions suggest an extremely important role for apoptosis in controlling cancer. This may be particularly important in the prostate where hypertrophy and/or cancer are a virtual certainty with ever-increasing age. It is not known whether the ability to undergo apoptosis declines in the prostate with increasing age, but it appears possible that it may, thus explaining the loss of control over cell number in this tissue. A particularly important area of research is whether apoptosis plays a role in the changing balance between bone formation and resorption observed during osteoporosis. Monica Driscoll has already pointed out that, "regulation and execution of cell death is an absolutely critical process that interfaces with nearly every aspect of life. Future investigation of the links of cell death to cellular aging and the aging of organisms should be an exciting enterprise." The results currently available do suggest that apoptosis is a process that may be important in aging, at least in some tissues, and the mechanism of its regulation, in particular, needs to be understood. Several tumor suppressor gene and oncogene products are involved in signal transduction associated with apoptosis, but it remains to be shown which of these, if any, are actually involved in "on-off" switches for apoptosis. Where great progress has been made is in understanding the events occurring after binding of either Fas ligand or tumor necrosis factor to their respective receptors. However, one area about which little is known is the identity of the signals that initiate this process in response to intracellular damage. Through continuing research on cell death mechanisms, funded by the NIA, we hope to provide answers to such fundamental questions as: 1. Are there age-related changes in apoptosis, and what role, if any, do these have in the aging process? 2. If age-related changes in apoptosis do occur, what molecular mechanisms are altered to produce these changes? 3. Can approaches be developed to improve the detection and elimination of damaged cells in vivo in tissues where cell replacement is possible? 4. Can death of damaged cells be attenuated or delayed in nonrenewable tissues, and, if so, is it advantageous to the org

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H R Warner, R J Hodes, K Pocinki. 1997. What does cell death have to do with aging?. https://doi.org/10.1111/j.1532-5415.1997.tb05981.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

An open benchmark and language models for AI in aging biology.

Over the past two decades, human aging has been characterized across DNA methylation, transcriptomic, proteomic, and clinical modalities, yet no benchmark evaluates whether AI systems can interpret these heterogeneous data types in the context of aging biology. We introduce LongevityBench, an open suite of 17 tasks spanning five biodata domains, and use it to assess 18 frontier AI systems from six developer teams. Despite recent advances in AI, no single model dominates all tasks, with omics-based age prediction being the hardest task regardless of scale. To test whether these gaps can be closed without frontier-scale resources, we fine-tuned a family of five multitask Longevity-LLMs on domain-specific aging data. The compact (0.6B-9B parameters) Longevity-LLMs matched or exceeded far larger frontier systems on LongevityBench, showing that general-purpose language models can be adapted to structured-omics tasks. We publicly release the benchmark, models, and Longevity Claw, an agentic research interface for aging researchers.

Aging↗

Association between sirtuin 1 and markers of oxidative stress in master athletes.

BACKGROUND: Lifelong training in master athletes confers protective effects, promoting higher sirtuin levels and enhanced antioxidant capacity. Although Sirtuin 1 (SIRT1) is well studied, no previous study has examined the relationship between circulating SIRT1 levels and antioxidant defense variables in master athletes. PURPOSE: To compare and analyze the relationships between circulating levels of SIRT1 and variables related to antioxidant defense in master athletes (MA) and untrained middle-aged individuals (UMA). METHODS: Male MA (n&#x2009;=&#x2009;42; 51.62&#x2009;&#xb1;&#x2009;7.33 years; &#x2265;10 years of training and competition in running) and UMA (n&#x2009;=&#x2009;15; 47.73&#x2009;&#xb1;&#x2009;8.52 years) were evaluated. Venous blood samples were collected for biochemical analyses of SIRT1, antioxidant enzymes, TBARS and F2-isoprostanes, 8-OHdG, and redox balance indexes. RESULTS: MA showed higher levels of SIRT1 (18.22&#x2009;&#xb1;&#x2009;4.53 vs. 6.08&#x2009;&#xb1;&#x2009;2.11 ng/mL; p&#x2009;<&#x2009;0.0001), as well as of SOD, CAT, and GSH (p&#x2009;<&#x2009;0.001), indicating a more favorable antioxidant profile. After adjustment for body fat percentage, differences in SOD, CAT, GSH and TBARS, remained significant. SIRT1 was positively correlated with SOD (r&#x2009;=&#x2009;0.279; p&#x2009;=&#x2009;0.031), CAT (r&#x2009;=&#x2009;0.485; p&#x2009;<&#x2009;0.001), GSH (r&#x2009;=&#x2009;0.476; p&#x2009;<&#x2009;0.001) and CAT/8-OHdG (r&#x2009;=&#x2009;0.430; p&#x2009;=&#x2009;0.032), and negatively correlated with TBARS (r&#x2009;=&#x2009;-&#x2009;0.518; p&#x2009;<&#x2009;0.001). CONCLUSION: Master athletes exhibited higher circulating SIRT1 concentrations and a more favorable systemic redox profile than untrained individuals, with SIRT1 being associated with markers of antioxidant defense, lipid peroxidation, and redox balance.

Aging↗

Decoding SUMOylation as a metabolic stress sensor in aging and age-related disorders: Mechanisms, tissue specificity and therapeutic potential.

SUMOylation is a reversible post-translational modification increasingly recognized for its role in coordinating cellular responses to metabolic stress during aging. Emerging evidence indicates that it functions beyond a conventional modification, representing an adaptive stress&#x2011;responsive regulatory network that integrates metabolic, oxidative, inflammatory, and proteotoxic signals. Rather than acting on isolated pathways, this network finely tunes mitochondrial function, proteostasis, genome maintenance, immune balance, and epigenetic regulation. Accumulating evidence indicates that SUMO-dependent regulation exhibits remarkable tissue specificity, supporting mitochondrial adaptation and contractile integrity in skeletal muscle, shaping lipid and glucose metabolism in the liver, modulating proteotoxic stress and neuronal resilience in the brain, and contributing to immune cell differentiation and chronic low-grade inflammation during aging. In this review, we summarize current mechanistic insights into SUMO signaling across aging-relevant tissues, with particular emphasis on its functional interplay with other post-translational modifications, including ubiquitination and acetylation. We discuss how SUMOylation operates as a shared regulatory layer while enabling context-dependent outcomes that underlie diverse aging phenotypes and age-related disorders. Finally, we evaluate emerging translational approaches-ranging from pharmacological modulation of SUMO enzymes to lifestyle interventions such as caloric restriction and exercise-that highlight both the opportunities and challenges of targeting SUMO-regulated stress responses in aging. Together, this synthesis provides a framework for understanding how SUMOylation links metabolic stress to tissue-specific aging trajectories and therapeutic potential.

Aging↗